Breaking News: FDA Shakes Up Drug Approval Process – But Is One Study Enough?
In a move that’s sure to spark debate, the Food and Drug Administration (FDA) is set to overhaul its decades-old drug approval process. Gone are the days of requiring two rigorous studies for new drugs – at least, that’s the plan according to FDA Commissioner Dr. Marty Makary and his deputy, Dr. Vinay Prasad. In a recent New England Journal of Medicine article, they argue that modern advancements in drug research have made the traditional two-trial standard outdated. But here's where it gets controversial: Is relying on a single study a step forward in efficiency, or a risky gamble with patient safety?
This shift is part of a broader effort by the Trump administration to slash red tape and accelerate the availability of medical products. Since joining the FDA last April, Makary has introduced a series of bold initiatives, including the use of artificial intelligence in reviews and expedited one-month assessments for drugs deemed to serve “national interests.” These changes stand in stark contrast to the FDA’s more cautious approach to vaccines and other treatments, leaving many to wonder: Why the double standard?
And this is the part most people miss: While the FDA has increasingly accepted single studies for rare or life-threatening diseases since the 1990s, this new policy extends that flexibility to common diseases. Over the past five years, roughly 60% of first-of-a-kind drugs have been approved based on just one study, thanks to congressional mandates for greater flexibility in reviewing treatments for serious conditions. But expanding this approach to more widespread ailments raises critical questions about reliability and reproducibility.
Former FDA drug director Dr. Janet Woodcock supports the change, noting that advancements in biology and disease understanding have made two trials unnecessary in many cases. However, she cautions that the devil is in the details: “Implementation will be everything,” she says. Meanwhile, the FDA’s recent back-and-forth with Moderna’s mRNA flu vaccine application highlights the agency’s internal tensions between speed and rigor. After initially rejecting the vaccine for insufficient data, the FDA reversed its decision when Moderna agreed to conduct an additional study in older adults. This inconsistency has left biotech companies—and the public—scratching their heads.
Here’s the real question: Will this new policy truly unleash a surge in drug development, as Makary and Prasad predict, or will it undermine the FDA’s gold standard of safety and efficacy? Critics argue that relying on a single study could lead to approvals based on flawed or incomplete data, while proponents see it as a necessary step to bring life-saving treatments to market faster. What do you think? Is this a bold leap forward or a dangerous shortcut? Let us know in the comments below!
